it has been shown to significantly inhibit growth of breast cancer in animal xenograft models and has shown partial responses in clinical trials with renal cell carcinoma rcc and several other tumour types it was approved for rcc by the u s food and drug administration after showing a modest increase in progression free survival though there have been reports of fatal adverse effects it has received approval for use as a treatment for renal cell carcinoma from us fda 27 january 2012 ema 13 september 2012 uk mhra 3 september 2012 and australian tga 26 july 2012 a phase ii clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer however pfizer reported on january 30 2009 that phase iii clinical trials of the drug when used in combination with gemcitabine showed no evidence of improved survival rates over treatments using gemcitabine alone for advanced pancreatic cancer and halted the trial in 2010 a phase iii trial for previously treated metastatic renal cell carcinoma mrcc showed significantly extended progression free survival when compared to sorafenib in december 2011 the oncologic drugs advisory committee odac voted unanimously to recommend that us fda approve axitinib for the